Substratum of follow-up time | Number of patients at start of period | Number of patients with at least one test for proteinuria during 1 year period (%)* | Time in months to the first test among patients with at least one test in the 1 year period (median, Q1–Q3) |
---|---|---|---|
Time since start of diabetic drug therapy† | |||
0 to ≤1st year | 65 790 | 49 707 (75.6) | 2.9 (0.5–6.3) |
>1 to ≤2nd year | 65 735 | 43 690 (66.5) | 4.0 (1.7–7.1) |
>2 to ≤3rd year | 50 705 | 32 895 (64.9) | 4.1 (1.8–7.1) |
>3 to ≤4th year | 36 948 | 22 848 (61.8) | 4.1 (1.8–7.0) |
>4 to <5th year | 23 879 | 13 993 (58.6) | 3.8 (1.7–6.8) |
Antidiabetic treatment period‡ | |||
1st treatment | 45 161 | 44 469 (98.5) | 4.0 (0.8–9.5) |
MET | 41 269 | 40 670 (98.5) | 4.0 (0.8–9.5) |
SU | 2506 | 2447 (97.6) | 4.0 (0.9–9.6) |
MET+SU | 845 | 830 (98.2) | 2.3 (0.3–6.9) |
2nd treatment | 15 046 | 14 062 (93.5) | 5.8 (2.3–10.6) |
MET+SU | 9511 | 8923 (93.8) | 5.8 (2.1–10.6) |
MET+DPP4I | 1945 | 1789 (92.0) | 5.7 (2.3–10.8) |
MET+PIO | 968 | 898 (92.8) | 6.5 (2.8–11.5) |
SU | 960 | 902 (94.0) | 5.8 (2.4–9.7) |
3rd treatment | 3986 | 3579 (89.8) | 6.1 (2.7–10.6) |
SU+DPP4I | 1261 | 1137 (90.2) | 6.0 (2.5–10.6) |
*Only patients who had at least one test for proteinuria during the specified period were counted.
†Only patients who had at least certain years of antidiabetic drug therapy were counted at start of period assessed. For example, 23 879 patients had at least 4 years since start of antidiabetic drug therapy.
‡Only treatment periods/courses that lasted for at least 1 year were counted; and only proteinuria tests that were performed within 1 year after initiation of each treatment period/course were counted. Data for the most frequently used antidiabetic drug treatment with at least 500 users were presented.
DPP4I, dipeptidyl peptidase 4 inhibitors; MET, metformin; PIO, pioglitazone; SU, sulfonylureas.